A membrane-permeable, reversible blocker of IP₃-mediated Ca²⁺ release (IC₅₀ = 648 nM) that is less potent than XeC (Cat. No. 682160). Also displays a high selectivity over the skeletal isoform of the ryanodine receptor type 1 (Ry1R).

A reversible, membrane-permeable blocker of IP₃-mediated Ca²⁺ release (IC₅₀ = 648 nM). Also displays high selectivity over the skeletal isoform of the ryanodine receptor type 1 (RyR-1).

Cell permeable: no

Primary Target
IP3-mediated Ca2+

Product does not compete with ATP.

Reversible: yes

Target IC₅₀: 648 nM in blocking IP3-mediated Ca2+ release

Sonication may be required to achieve complete solubilization.

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Gafni, J., et al. 1997. Neuron 19, 723.
Tinker, A., and Williams, A.J. 1995. Biophys. J. 68, 111.
Callaway, C., et al. 1994. J. Biol. Chem. 269, 15876.
Quirion, J.C., et al. 1992. J. Nat. Prod. 55, 1505.
Nakagawa, M., et al. 1984. Tetrahedron Lett.25, 3227

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Toxicity: Harmful (C)